Table 1.

AZGP1 levels and clinicopathological features in 74 ICC patients.

Variables	AZGP1 expression
	Total (n = 74)	Low expression (n = 54)	High expression (n = 20)	P value
Age, years, Mean ± SD	65.81 ± 9.89	65.91 ± 9.81	65.55 ± 10.37	0.891
Gender, N (%)
Male	31 (41.9)	32 (59.3)	11 (55.0)	0.742
Female	43 (58.1)	22 (40.7)	9 (45.0)
HBsAg, N (%)				0.702
Negative	47 (63.5)	35 (64.8)	12 (60.0)
Positive	27 (36.5)	19 (35.2)	8 (40.0)
AFP, ng/mL, (IQR)	2.76 (2.1–3.62)	2.93 (2.09–3.7)	2.7 (2.11–3.55)	0.733
CEA, μg/L, (IQR)	2.75 (1.65–7.63)	2.85 (1.65–9.88)	2.25 (1.55–4.18)	0.461
CA19-9, U/mL, (IQR)	104.85 (18.97–711.68)	104.85 (18.97–857.93)	111.65 (9.63–527.9)	0.756
TNM Stage, N (%)
I-II	58 (78.4)	40 (74.1)	18 (90.0)	0.139
III-IV	16 (21.6)	14 (25.9)	2 (10.0)
Tumor differentiation, N (%)				0.588
Well	52 (70.3)	37 (68.5)	15 (75.0)
Poor	22 (29.7)	17 (31.5)	5 (25.0)
Tumor location, N (%)
Left	46 (62.2)	29 (53.7)	17 (85.0)	0.014
Right	28 (37.8)	25 (46.3)	3 (15.0)
Tumor size, cm, N (%)				0.872
≤5.0 cm	47 (63.5)	34 (63.0)	13 (65.0)
å 5.0 cm	27 (36.5)	20 (37.0)	7 (35.0)
Tumor number, N (%)				0.48
Single	66 (89.2)	49 (90.7)	17 (85.0)
Multiple	8 (10.8)	5 (9.3)	3 (15.0)
Vascular invasion, N (%)				0.321
No	57 (77.0)	40 (74.1)	17 (85.0)
Yes	17 (23.0)	14 (25.9)	3 (15.0)
Perineural invasion, N (%)				0.934
No	56 (75.7)	41 (75.9)	15 (75.0)
Yes	18 (24.3)	13 (24.1)	5 (25.0)
Lymph node metastasis, N (%)				0.147
No	63 (85.1)	44 (81.5)	19 (95.0)
Yes	11 (14.9)	10 (19.5)	1 (5.0)
AZGP1, N (%)
High	20 (27.0)	0 (0.0)	20 (100.0)
Low	54 (73.0)	54 (100.0)	0 (0.0)
Vital status, N (%)				0.012
Alive	35 (47.3)	24 (44.4)	11 (55.0)
Dead	39 (52.7)	30 (55.6)	9 (45.0)
Diabetes, N (%)
No	60 (81.1)	41 (75.9)	19 (95.0)	0.063
Yes	14 (18.9)	13 (24.1)	1 (5.0)

Bold values indicates statistically significant p values less than 0.05.